NK Cells in Cancer Immunotherapy: Successes and Challenges. Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy Volume 4


Book
December 2022
Elsevier Science and Technology
ID: 5146473

NK Cells in Cancer Immunotherapy: Successes and Challenges explains the latest immunotherapeutic strategies, focusing on NK cells to allow the best and precise combination treatments to cancer patients. The book provides existing background knowledge in the field of immunotherapy and discusses future areas of research required to carry out cutting-edge, validated therapies. Chapters cover advances in immunotherapeutic strategies, in particular, the use of NK cells with and without T-cell therapy in the treatment of cancer. The book is a valuable resource for cancer researchers, oncologists, graduate students and those interested in learning more about novel strategies to treat cancer patients.

Immunotherapy is fast becoming the method of choice for cancer therapy. Although remarkable advances have been made in the field of immunotherapy, there are significant challenges and difficulties ahead since many of the current immunotherapeutic strategies do not provide long-lasting treatment strategies, and therefore are not very effective.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

1. Introduction and basic biology of NK cells2. Immunotherapy using CAR/NK with and without CAR/T3. Immunotherapy using NK cells with and without T cells and Tumor infiltrating lymphocytes as well as NK/T cells4. Autologous vs allogeneic sources of NK and T cell effectors5. Reversing NK inhibitory tumor microenvironment by targeting suppressive immune effectors6. Check point inhibitors7. Combination of NK immunotherapy with chemotherapy and radiation8. NK cell immunotherapy using ADCC inducing antibodies9. Oncolytic viruses and NK cell immunotherapy10. NK cell diagnostics11. Novel cell delivery systems

Authors

Anahid Jewett National Institute of Health Study Sections, UCLA, USA. Dr. Anahid Jewett, PhD, MPH, is well-known nationally and internationally for her contribution to the field of NK biology, tumor immunology and cancer immunotherapy. She serves on the editorial board of many prestigious journals and has been a reviewer on the board of National Institute of Health study sections. She holds several patents and has published more than 100 high impact journal articles, reviews, commentaries and book chapters in the field of cancer. Dr. Jewett's major contributions to science and NK cell biology were the identification, characterization and the establishment of the concept of split anergy in NK cells, establishment of the role of NK cells in elimination, selection and differentiation of cancer stem cells as well as healthy stem cells, and methods to generate large numbers of super-charged NK cells which are in use currently in clinical trials of cancer patients. Yuman Fong Attending Surgeon, Memorial Sloan-Kettering Cancer Center; Professor of Surgery, Weill Medical College of Cornell University, New York, NY.

Table of Contents

Authors

Related Topics

Related Products

NK Cell therapies - Pipeline Insight, 2024

IPSC derived NK cells - Pipeline Insight, 2024

Cellular Immunotherapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

Cellular Immunotherapy Global Market Report 2024

Global Cellular Immunotherapy Market by Type (CAR T-Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy), Indication (B-Cell Malignancies, Liver Cancer, Prostate Cancer), Technology Type, End-Use - Forecast 2024-2030